Russell Ross, 1929-1999

Article Abstract:

Russell Ross, until 1994 the Chairman of the Department of Pathology at the University of Washington, also on the faculty of the Department of Biochemistry, was prominent in the study of pathogenesis of atherosclerosis, a gifted speaker, a supporter of the arts, and a fine friend to many colleagues. In his last years he led the charge to adopt mouse models in learning about atherogenesis. He was a champion of vascular biology and atherosclerosis research, an enthusiastic and articulate advocate for his field.

Washington, Research, Obituary, Officials and employees, Achievements and awards, College teachers, College faculty, Medical research, Atherosclerosis, Biochemists, Pathologists, University of Washington, Ross, Russell

---

Spinal cord injury: are interleukins a molecular link between neuronal damage and ensuing pathobiology?

Article Abstract:

Interleukins arepeptides or glycoproteins that modify the growth and behavior of cells of the immune system. The pathogenesis of the diverse sequelae of spinal cord injury such as impaired cardiopulmonary functions, anemia, altered hepatic metabolism,immune incompetence, carbohydrate intolerance, changes in pharmacokinetics, accelerated bone turnover and impaired thermoregulation may be explained by mediation of interleukins, specifically interleukins 1 and 2.

Physiological aspects, Interleukins, Interleukin-1, Interleukin-2, Spinal cord, Nervous system diseases

---

Similar abstracts:

• Abstracts: Vulnerable Plaque: Pathobiology and Clinical Implications. A registry for clinical trials
• Abstracts: Changing clinical practice. Changing urine testing protocols through audit
• Abstracts: Determinants of dengue 2 infections among residents of charters towers, Queensland, Australia. part 2 Tuberculin skin testing among economically disadvantaged youth in a federally funded job training program
• Abstracts: Medical, Legal, and Societal Implications of Androstenedione Use. Creatine and androstenedione -- two "dietary supplements."
• Abstracts: Tamoxifen for prevention of breast cancer. Valrubicin for bladder cancer. Trastuzumab and capecitabine for metastatic breast cancer

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.